Sodium Fluoride F 18
SODIUM FLUORIDE F 18- sodium fluoride f-18 injection
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH
1 INDICATIONS AND USAGE
Sodium Fluoride F 18 Injection, USP is indicated for diagnostic positron emission tomography (PET) imaging of bone to define areas of altered osteogenic activity.
2 DOSAGE AND ADMINISTRATION
2.1 Radiation Safety — Drug Handling
• Wear waterproof gloves and effective shielding when handling Sodium Fluoride F 18 Injection, USP. Use appropriate safety measures, including shielding, consistent with proper patient management to avoid unnecessary radiation exposure to the patient, occupational workers, clinical personnel, and other persons.
• Radiopharmaceuticals should be used by or under the control of physicians who are qualified by specific training and experience in the safe use and handling of radionuclides, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radionuclides.
• Use aseptic technique to maintain sterility during all operations involved in the manipulation and administration of Sodium Fluoride F 18 Injection, USP.
• The dose of Sodium Fluoride F 18 Injection, USP should be minimized consistent with the objectives of the procedure, and the nature of the radiation detection devices employed.
• The final dose for the patient should be calculated using proper decay factors from the time of End of Synthesis (EOS), and measured by a suitable radioactivity calibration system before administration [see Description (11.2)].
2.2 Radiation Safety — Patient Preparation
• To minimize radiation-absorbed dose to the bladder, encourage adequate hydration. Encourage the patient to ingest at least 500 mL of fluid immediately prior and subsequent to the administration of Sodium Fluoride F 18 Injection, USP.
• Encourage the patient to void one-half hour after administration of Sodium Fluoride F 18 Injection, USP and as frequently thereafter as possible for the next 12 hours.
2.3 Drug Preparation and Administration
• Calculate the necessary volume to administer based on calibration time and dose.
• Inspect Sodium Fluoride F 18 Injection, USP visually for particulate matter and discoloration before administration, whenever solution and container permit.
• Do not administer Sodium Fluoride F 18 Injection, USP containing particulate matter or discoloration; dispose of these unacceptable or unused preparations in a safe manner, in compliance with applicable regulations.
• Aseptically withdraw Sodium Fluoride F 18 Injection, USP from its container.
2.4 Recommended Dose for Adults
Administer 296-444 MBq (8-12 mCi) as an intravenous injection.
2.5 Recommended Dose for Pediatric Patients
In reported clinical experience in approximately 100 children, weight based doses (2.1 MBq/kg) ranging from 18.5 MBq-148 MBq (0.5 mCi-4 mCi) were used.
2.6 Radiation Dosimetry
The age/weight-based estimated absorbed radiation doses (mGy/MBq) from intravenous injection of Sodium Fluoride F 18 Injection, USP are shown in Table 1. These estimates were calculated based on human data and using the data published by the Nuclear Regulatory Commission  and the International Commission on Radiological Protection for Sodium Fluoride Injection . The bone, bone marrow, and urinary bladder are considered target and critical organs.
|Organ||Estimated Radiation Dose mGy/MBq|
70 kg 
56.8 kg 
33.2 kg 
19.8 kg 
9.7 kg 
|Upper large intestine wall||0.0058||0.010||0.016||0.026||0.046|
|Lower large intestine wall||0.012||0.016||0.025||0.037||0.063|
|Urinary bladder wall||0.25||0.27||0.4||0.61||1.1|
|Effective Dose Equivalent mSv/MBq||0.027||0.034||0.052||0.086||0.17|
 Data from Nuclear Regulatory Commission Report, Radiation Dose Estimates for Radiopharmaceuticals , NUREG/CR-6345, page 10, 1996.
 Data from ICRP publication 53, Radiation Dose to Patients from Radiopharmaceuticals , Ann ICRP, Volume 18, pages 15 and 74, 1987.
2.7 Imaging Guidelines
• Imaging of Sodium Fluoride F 18 Injection, USP can begin 1-2 hours after administration; optimally at 1 hour post administration.
• Encourage the patient to void immediately prior to imaging the fluoride F 18 radioactivity in the lumbar spine or bony pelvis.
3 DOSAGE FORMS AND STRENGTHS
Multiple-dose vial containing 740-22,200 MBq/mL (20-600 mCi/mL) at EOS reference time of no-carrier-added sodium fluoride F 18 in aqueous 0.9% sodium chloride solution. Sodium Fluoride F 18 Injection, USP is a clear, colorless, sterile, pyrogen-free, and preservative-free solution for intravenous administration.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.